MX2010002938A - Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. - Google Patents

Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.

Info

Publication number
MX2010002938A
MX2010002938A MX2010002938A MX2010002938A MX2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A
Authority
MX
Mexico
Prior art keywords
treating
beta
butan
thiazol
pyrrolidine
Prior art date
Application number
MX2010002938A
Other languages
English (en)
Spanish (es)
Inventor
Arun K Ghosh
Geoffrey M Bilcer
Chunfeng Liu
Thippeswamy Devasamudram
Hui Lei
Lisa M Swanson
Sudha V Ankala
John C Lilly
Original Assignee
Comentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comentis Inc filed Critical Comentis Inc
Publication of MX2010002938A publication Critical patent/MX2010002938A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2010002938A 2007-09-24 2008-09-24 Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. MX2010002938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97479307P 2007-09-24 2007-09-24
PCT/US2008/077537 WO2009042694A1 (en) 2007-09-24 2008-09-24 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating

Publications (1)

Publication Number Publication Date
MX2010002938A true MX2010002938A (es) 2010-04-01

Family

ID=40343545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002938A MX2010002938A (es) 2007-09-24 2008-09-24 Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.

Country Status (8)

Country Link
US (1) US8299267B2 (enExample)
EP (1) EP2205596A1 (enExample)
JP (1) JP5055432B2 (enExample)
KR (1) KR20100059919A (enExample)
CN (1) CN101868457B (enExample)
CA (1) CA2699787A1 (enExample)
MX (1) MX2010002938A (enExample)
WO (1) WO2009042694A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101868457B (zh) 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
RU2594155C2 (ru) * 2009-09-04 2016-08-10 Тэктикал Терапеутикс, Инк Новые композиции и способы получения 5-амино- или замещенных амино-1,2,3-триазолов и триазол-оротатных композиций
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
JP2013506713A (ja) * 2009-10-05 2013-02-28 コメンティス,インコーポレーテッド β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US20120053200A1 (en) * 2010-09-01 2012-03-01 Harald Mauser Bace 2 inhibitors
ES2563861T3 (es) 2012-06-14 2016-03-16 Daiichi Sankyo Company, Limited Derivado de piperidinilpirazolopiridina
CN105669365B (zh) * 2016-03-04 2022-06-21 中国科学院上海有机化学研究所 含二氟烷基取代的芳基或杂芳基化合物、制备方法和应用
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN110117237B (zh) * 2018-02-05 2024-02-02 中国科学院上海有机化学研究所 一种芳香腈或烯基腈类化合物的制备方法
CN110642789B (zh) * 2019-11-25 2020-05-26 天津凯莱英制药有限公司 2-氯嘧啶-4-甲酸类化合物的连续性合成方法
CN112321515A (zh) * 2020-10-21 2021-02-05 上海馨远医药科技有限公司 一种手性1-叔丁基-3-甲基-6-甲基哌嗪-1,3-二甲酸酯的制备方法
WO2023149945A1 (en) * 2022-02-03 2023-08-10 Purdue Research Foundation Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use
US12191004B2 (en) 2022-06-27 2025-01-07 Microsoft Technology Licensing, Llc Machine learning system with two encoder towers for semantic matching

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
TW282460B (enExample) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
EP1237872B1 (en) 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL151910A0 (en) 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
EP1404718A2 (en) 2000-12-28 2004-04-07 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
WO2002064558A2 (en) 2001-02-14 2002-08-22 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
US20060234944A1 (en) 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
EP1448218A4 (en) 2001-10-23 2009-01-14 Oklahoma Med Res Found BETA SECRETASE INHIBITORS AND METHOD OF USE
AR039555A1 (es) 2001-11-08 2005-02-23 Upjohn Co Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
WO2003050073A1 (en) 2001-12-06 2003-06-19 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
HRP20040857A2 (en) 2002-02-27 2005-06-30 Pharmacia & Upjohn Company Elan Pharmaceuticals Substituted hydroxyethylamines
AU2003220115A1 (en) 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
RU2357962C2 (ru) 2002-09-06 2009-06-10 Элан Фармасьютикалз, Инк. Пролекарственные производные 1,3-диамино-2-гидроксипропана
DE60329316D1 (de) 2002-11-12 2009-10-29 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
CA2534950A1 (en) 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Bace 저해효능을 가진 신규한 술폰 아미드 유도체
JP2007517781A (ja) 2003-12-19 2007-07-05 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
EP1758854B1 (en) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US7659289B2 (en) 2004-09-17 2010-02-09 Comentis, Inc. Hydroxyethylene-based β-secretase inhibitors and use thereof
JP2008513495A (ja) 2004-09-17 2008-05-01 コメンティス,インコーポレーテッド ベータ−セクレターゼ活性を阻害する二環式化合物およびその使用方法
CN100475786C (zh) * 2005-02-18 2009-04-08 中国科学院上海药物研究所 一类4-羟基戊酰胺类化合物及其制备方法和用途
WO2006099352A1 (en) 2005-03-10 2006-09-21 Bristol-Myers Squibb Company Novel isophthalates as beta-secretase inhibitors
MX2007012341A (es) 2005-04-08 2008-02-12 Comentis Inc Compuestos que inhiben actividad beta-secretasa y metodos de uso de los mismos.
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR054363A1 (es) 2005-05-23 2007-06-20 Astrazeneca Ab Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6
AR054044A1 (es) 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US7476764B2 (en) 2005-08-04 2009-01-13 Bristol-Myers Squibb Company Phenylcarboxyamides as beta-secretase inhibitors
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
CA2664130A1 (en) 2006-09-21 2008-03-27 Merck & Co., Inc. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2178837A2 (en) 2007-07-26 2010-04-28 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
CN101868457B (zh) 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
EP2307345A4 (en) 2008-07-01 2012-05-02 Purdue Research Foundation NON-PEPTIDINHIBITORS OF HIV-1 PROTEASE
US20130102593A1 (en) 2008-10-10 2013-04-25 Geoffrey M. Bilcer Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
JP2012505241A (ja) 2008-10-10 2012-03-01 パーデュー・リサーチ・ファウンデーション アルツハイマー病の治療用組成物
EP2376083A4 (en) 2008-11-20 2012-06-20 Purdue Research Foundation QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
WO2010065861A2 (en) 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
EP2411000A4 (en) 2009-03-25 2012-09-19 Comentis Inc PYRROLIDIN COMPOUNDS FOR INHIBITING THE BETA-SECRETASE EFFECT AND METHOD FOR THE APPLICATION THEREOF
JP2013506713A (ja) 2009-10-05 2013-02-28 コメンティス,インコーポレーテッド β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法

Also Published As

Publication number Publication date
WO2009042694A1 (en) 2009-04-02
JP2010540462A (ja) 2010-12-24
CA2699787A1 (en) 2009-04-02
EP2205596A1 (en) 2010-07-14
US20100286170A1 (en) 2010-11-11
CN101868457B (zh) 2013-02-13
KR20100059919A (ko) 2010-06-04
CN101868457A (zh) 2010-10-20
JP5055432B2 (ja) 2012-10-24
US8299267B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
NO20083207L (no) Inhibitorer av IAP
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2010007543A (es) Inhibidores de iap.
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
TW200745066A (en) Novel PTP1B inhibitors
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
FG Grant or registration